Medicare’s Combo Products Negotiation Plan Conflicts With US FDA Standards, Firms Argue

 
• By Cathy Kelly
  
The policy could threaten Medicare Part B oncology drug line extensions. (Shutterstock)

More from Medicare

More from Government Payers